Atlas Trials

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Clinical trial NCT00458367 · COMPLETED

Trial details

NCT number
NCT00458367
Sponsor
Janssen Pharmaceutica N.V., Belgium
Status
COMPLETED
Study type
OBSERVATIONAL
SchizophreniaPsychotic DisordersSchizoaffective Disorder
Start date
2002-06-01
Enrollment
5296

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.